EAU 2025 | Professors Haige Chen and Ruiyun Zhang Share Advances in Non-Invasive Bladder-Sparing Detection and Targeted-Immunotherapy Combinations

EAU 2025 | Professors Haige Chen and Ruiyun Zhang Share Advances in Non-Invasive Bladder-Sparing Detection and Targeted-Immunotherapy Combinations

Trimodality therapy (TMT)is a well-established bladder-sparing strategy for patients with muscle-invasive bladder cancer (MIBC). However, limitations remain for patients intolerant to chemotherapy and in monitoring post-treatment recurrence. Professors Haige Chen and Ruiyun Zhang of Renji Hospital, Shanghai Jiao Tong University School of Medicine, have long focused on MIBC research. This year, nine of their studies were accepted at the EAU Congress. UroStream invited Professors Chen and Zhang to share their insights on emerging approaches, including chemotherapy-free strategies combining the domestic ADC drug RC48 with PD-1 inhibitors, the value of utDNA in non-invasive monitoring, AI-based molecular subtyping, and major takeaways from the congress.
SGBCC 2025 | Prof. Zefei Jiang has an in-depth dialogue with Prof. Michael Gnant: Combining Chinese and Western Approaches and Listening to the Voice of China at SGBCC

SGBCC 2025 | Prof. Zefei Jiang has an in-depth dialogue with Prof. Michael Gnant: Combining Chinese and Western Approaches and Listening to the Voice of China at SGBCC

From March 12 to 15, 2025, the 19th St. Gallen Breast Cancer Conference (SGBCC) was held with great success. During the conference, the Chinese Society of Clinical Oncology (CSCO) and SGBCC jointly organized the "Voice of China" session, showcasing China's advancements in clinical research, basic science, translational medicine, and radiomics within the breast cancer field, which sparked vibrant discussions among global experts. “Oncology Frontier” invited the co-chairs of this session—Prof. Zefei Jiang (St.Gallen International Consensus panel Member, CSCO President-Elect, Chinese PLA General Hospital) and Prof. Michael Gnant (SGBCC Conference Chair, Comprehensive Cancer Center, Medical University of Vienna)—to engage in a profound dialogue on the future of Sino-global collaboration.
Professor Ying Fan Wins SGBCC Best Poster Award for Real-World Study on HER2-Positive Breast Cancer in the Neoadjuvant Setting

Professor Ying Fan Wins SGBCC Best Poster Award for Real-World Study on HER2-Positive Breast Cancer in the Neoadjuvant Setting

The 19th St. Gallen Breast Cancer Conference (SGBCC), held in Vienna from March 12 to 15, 2025, remains one of the most influential global platforms in early breast cancer care. Among seven studies awarded the prestigious Best Poster Award, four came from China, including a multi-center real-world study led by Professor Ying Fan from the Cancer Hospital Chinese Academy of Medical Sciences. Her research focused on treatment-insensitive HER2-positive breast cancer patients undergoing neoadjuvant therapy. Oncology Frontier spoke with Professor Fan to learn more about the study’s results, and broader implications.
EAU 2025 | CUHK’s Peter Chiu and Team Highlight Advances in Precision Biopsy and Standardized Treatment for Prostate Cancer

EAU 2025 | CUHK’s Peter Chiu and Team Highlight Advances in Precision Biopsy and Standardized Treatment for Prostate Cancer

Prostate cancer remains one of the most prevalent malignancies threatening men’s health worldwide. A major research focus today lies in developing accurate screening and diagnostic strategies that minimize the invasiveness and psychological burden of biopsy procedures. Landmark studies like SMART and PRECISION aim to address these challenges. At the 2025 European Association of Urology (EAU) Annual meeting, Professor Chiu Ka Fung Peter from the Department of Urology at The Chinese University of Hong Kong presented the latest findings from the SMART study. Following his presentation, Professor Chiu spoke with UroStream to share key updates in prostate cancer diagnostics and care.